Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts rate Rezolute a "Hold": 11 brokerages cover RZLT (1 sell, 5 hold, 5 buy) with an average 1‑year target of about $7.63.
• Recent results and outlook are weak: Rezolute reported Q EPS of ($0.22) vs. ($0.16) expected and analysts forecast ~($0.93) EPS for the year; the stock trades around $2.49 with a market cap of ~$238M and a 52‑week range of $1.07–$11.46.
• Rezolute is a clinical‑stage biopharma: its lead candidate RZ358 is in Phase 2b for congenital hyperinsulinism and RZ402 is in trials for diabetic macular edema, while institutional investors own roughly 83% of the shares.

Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have earned a consensus rating of "Hold" from the eleven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $7.6250.

Several equities research analysts have recently commented on RZLT shares. BTIG Research reissued a "buy" rating and set a $5.00 price target on shares of Rezolute in a research note on Thursday, January 8th. Guggenheim reduced their price objective on Rezolute from $15.00 to $6.00 and set a "buy" rating for the company in a report on Friday, December 12th. Cantor Fitzgerald downgraded Rezolute from an "overweight" rating to a "neutral" rating in a research report on Thursday, December 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Rezolute in a report on Thursday, January 22nd. Finally, Wedbush raised their price target on Rezolute to $2.00 and gave the company a "neutral" rating in a research report on Thursday, January 8th.

Institutional Investors Weigh In On Rezolute

A number of large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in Rezolute during the second quarter worth about $25,000. ExodusPoint Capital Management LP acquired a new stake in shares of Rezolute in the fourth quarter valued at approximately $25,000. HB Wealth Management LLC acquired a new stake in shares of Rezolute in the fourth quarter valued at approximately $26,000. Fifth Third Wealth Advisors LLC purchased a new position in shares of Rezolute during the 4th quarter worth approximately $29,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Rezolute during the 4th quarter worth approximately $29,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Trading Up 0.6%

RZLT stock opened at $2.49 on Friday. The company has a market cap of $237.81 million, a P/E ratio of -2.67 and a beta of 0.51. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46. The company's 50-day moving average price is $3.12 and its 200 day moving average price is $5.94.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.06). On average, equities research analysts expect that Rezolute will post -0.93 earnings per share for the current year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.